Panitumumab outcome by tumour location analysis
PRIME study: OS
•
Boeckx N, et al. Ann Oncol 2016;27(Suppl 6):abstract 89P (and poster).
3: Pmab + FOLFOX right side
1: Pmab + FOLFOX left side
68
64
60
56
52
48
44
40
36
32
28
24
20
16
12
8
4
0
0
20
40
60
80
100
Kaplan–Meier estimate
Months
0
1
0
3
1
1
0
11
6
1
1
16
11
3
1
30
19
4
4
39
21
4
5
46
24
4
6
56
32
5
7
66
44
6
8
77
56
8
9
86
64
11
11
97
76
13
14
107
86
15
20
124
103
17
23
136
120
18
28
147
137
26
34
164
151
36
42
169
159
39
49
1:
2:
3:
4:
No. of subjects
2: FOLFOX left side
4: FOLFOX right side
Median OS, months
Pmab + FOLFOX
FOLFOX
HR (95% CI)
Left
30.3
23.6
0.73 (0.57‒0.93)
Right
11.1
15.4
0.87 (0.55‒1.37)
WT
RAS
